Evan Vosburgh, MD
he/him/his
Associate Clinical Professor of MedicineDownloadHi-Res Photo
About
Titles
Associate Clinical Professor of Medicine
Biography
Evan Vosburgh, MD is a board certified hematologist and oncologist whose clinical activities include hematology and oncology clinical care at the West Haven Veterans Hospital, and primary care attending at the Yale Primary Care Center Wednesday Evening Clinic. Research interests include neuroendocrine cancers, amyloidosis, and clotting disorders.
Appointments
Medical Oncology
Associate Clinical ProfessorPrimary
Other Departments & Organizations
Education & Training
- Fellow
- Boston University School of Medicine (1989)
- MD
- Albany Medical College (1982)
- BS
- Duke University (1977)
Board Certifications
Medical Oncology
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 1989
Internal Medicine
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 1986
Research
Overview
Clinical benign and malignant hematology; neuroendocrine tumor biology; clinical research
ORCID
0000-0002-1728-7787
Research at a Glance
Yale Co-Authors
Frequent collaborators of Evan Vosburgh's published research.
Publications Timeline
A big-picture view of Evan Vosburgh's research output by year.
Joseph Paul Eder, MD
Josephine Hoh, PhD
35Publications
1,223Citations
Publications
2022
Tumors of the Diffuse Neuroendocrine and Gastroenteropancreatic System
Vosburgh E. Tumors of the Diffuse Neuroendocrine and Gastroenteropancreatic System. 2022, 1-10. DOI: 10.1002/9781119000822.hfcm083.pub2.Peer-Reviewed Original ResearchConceptsPeptide receptor radiotherapyMultiple endocrine neoplasiaDiffuse neuroendocrine systemClinical featuresHepatic metastasesNeuroendocrine tumorsGastroenteropancreatic systemNeuroendocrine systemInformed clinical careUnique clinical syndromeOngoing clinical trialsAbsence of symptomsCancer registry dataUnexplained incidenceReceptor radiotherapyClinical presentationRandomized trialsTherapeutic optionsClinical syndromeMultiple myelomaSomatostatin analoguesSpecific therapyRecent trialsSurvival resultsClinical trials
2020
Genetic analysis of the cooperative tumorigenic effects of targeted deletions of tumor suppressors Rb1, Trp53, Men1, and Pten in neuroendocrine tumors in mice
Xu EY, Vosburgh E, Wong C, Tang LH, Notterman DA. Genetic analysis of the cooperative tumorigenic effects of targeted deletions of tumor suppressors Rb1, Trp53, Men1, and Pten in neuroendocrine tumors in mice. Oncotarget 2020, 11: 2718-2739. PMID: 32733644, PMCID: PMC7367653, DOI: 10.18632/oncotarget.27660.Peer-Reviewed Original ResearchCitationsAltmetricConceptsTumor suppressor geneCooperative functionMolecular mechanismsTumor suppressor RB1Tumorigenic effectsCre-loxP systemGenetic analysisPTEN pathwaySuppressor geneGenesNeuroendocrine tumorigenesisGenetic alterationsDeletionPTENTrp53MeninHomozygous deletionExpressing cellsPathwayPRBSignificant roleMiceTumorigenesisPreclinical murine modelsMechanism
2019
Two well-differentiated pancreatic neuroendocrine tumor mouse models
Wong C, Tang LH, Davidson C, Vosburgh E, Chen W, Foran DJ, Notterman DA, Levine AJ, Xu EY. Two well-differentiated pancreatic neuroendocrine tumor mouse models. Cell Death & Differentiation 2019, 27: 269-283. PMID: 31160716, PMCID: PMC7206057, DOI: 10.1038/s41418-019-0355-0.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsMultiple endocrine neoplasia type 1Neuroendocrine tumorsMouse modelShort latencyPI3K/Akt/mTORPancreatic neuroendocrine tumorsPituitary neuroendocrine tumorsTumor mouse modelAkt/mTORMTOR inhibitor rapamycinCre-loxP systemNeuroendocrine cancerProlonged survivalProlonged latencyMEN1 patientsMouse insulin 1 promoterSame miceMen1 lossTherapeutic opportunitiesType 1Genetic syndromesPTEN lossEarly onsetTumorsTumor developmentAlleles of Insm1 determine whether RIP1-Tag2 mice produce insulinomas or nonfunctioning pancreatic neuroendocrine tumors
Kobayashi S, Contractor T, Vosburgh E, Du YN, Tang LH, Clausen R, Harris CR. Alleles of Insm1 determine whether RIP1-Tag2 mice produce insulinomas or nonfunctioning pancreatic neuroendocrine tumors. Oncogenesis 2019, 8: 16. PMID: 30796198, PMCID: PMC6386750, DOI: 10.1038/s41389-019-0127-1.Peer-Reviewed Original ResearchCitationsConceptsPancreatic neuroendocrine tumorsNeuroendocrine tumorsRIP1-Tag2 transgenic miceBeta-cell transcription factorsRIP1-Tag2 miceC57BL/6 genetic backgroundCell linesExpression of Insm1Stem cell markersLiver metastasesNonfunctioning tumorsB6 miceLarge tumorsMetastatic tumorsSevere diseaseRT2 miceAnimal modelsInsulinomaTransgenic miceCell transcription factorsInsulin productionGenetic backgroundTumorsHuman insulinomasCell markers
2017
Tumors of the Diffuse Neuroendocrine and Gastroenteropancreatic System
Vosburgh E. Tumors of the Diffuse Neuroendocrine and Gastroenteropancreatic System. 2017, 1-12. DOI: 10.1002/9781119000822.hfcm083.ChaptersConceptsDiffuse neuroendocrine systemClinical featuresNeuroendocrine tumorsGastroenteropancreatic systemProgression-free survival benefitNeuroendocrine systemMultiple endocrine neoplasia syndromeInformed clinical careUnique clinical syndromeFive-year survivalOngoing clinical trialsAbsence of symptomsCancer registry dataEndocrine neoplasia syndromeUnexplained incidenceSurvival benefitClinical presentationHepatic metastasesClinical syndromeMultiple myelomaSurvival resultsClinical trialsRegistry dataNeoplasia syndromeClinical care
2016
Sexual dimorphism of liver metastasis by murine pancreatic neuroendocrine tumors is affected by expression of complement C5
Contractor T, Kobayashi S, da Silva E, Clausen R, Chan C, Vosburgh E, Tang LH, Levine AJ, Harris CR. Sexual dimorphism of liver metastasis by murine pancreatic neuroendocrine tumors is affected by expression of complement C5. Oncotarget 2016, 7: 30585-30596. PMID: 27105526, PMCID: PMC5058703, DOI: 10.18632/oncotarget.8874.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsComplement C5Liver metastasesAdvanced tumorsNeuroendocrine tumorsMouse modelSmall primary tumorsPancreatic neuroendocrine tumorsTypes of tumorsSmall molecule antagonistsIntratumoral levelsPrimary tumorMale miceComplement C5aMetastasisTumorsMolecule antagonistsMiceHigh frequencySexual dimorphismHuman diseasesMalesFirst reportCD88CD68PMX53
2014
High-throughput Image Analysis of Tumor Spheroids: A User-friendly Software Application to Measure the Size of Spheroids Automatically and Accurately
Chen W, Wong C, Vosburgh E, Levine AJ, Foran DJ, Xu EY. High-throughput Image Analysis of Tumor Spheroids: A User-friendly Software Application to Measure the Size of Spheroids Automatically and Accurately. Journal Of Visualized Experiments 2014, 51639. PMID: 25046278, PMCID: PMC4212916, DOI: 10.3791/51639.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsGraphical user interfaceLarge-scale image analysisImage analysis applicationsUser-friendly software applicationFree image analysis softwareImage analysisActive contour algorithmHigh-throughput image analysisHigh-throughput computationTime-consuming processUser interfaceSoftware applicationsImage analysis softwareAnalysis applicationsNumber of applicationsUneven illuminationQuality control workflowContour algorithmAnalysis softwareQuality imagesNoisy backgroundSoftwareAnalysis processImagesEasy quality controlHigh-throughput Image Analysis of Tumor Spheroids: A User-friendly Software Application to Measure the Size of Spheroids Automatically and Accurately
Chen W, Wong C, Vosburgh E, Levine A, Foran D, Xu E. High-throughput Image Analysis of Tumor Spheroids: A User-friendly Software Application to Measure the Size of Spheroids Automatically and Accurately. Journal Of Visualized Experiments 2014 DOI: 10.3791/51639-v.Peer-Reviewed Original Research
2012
Human Neuroendocrine Tumor Cell Lines as a Three-Dimensional Model for the Study of Human Neuroendocrine Tumor Therapy
Wong C, Vosburgh E, Levine AJ, Cong L, Xu EY. Human Neuroendocrine Tumor Cell Lines as a Three-Dimensional Model for the Study of Human Neuroendocrine Tumor Therapy. Journal Of Visualized Experiments 2012, 4218. PMID: 22929519, PMCID: PMC3486771, DOI: 10.3791/4218.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsNeuroendocrine tumorsNET cell linesDrug treatmentCell linesMetastatic neuroendocrine tumorsMinority of patientsHuman neuroendocrine tumor cell linesNeuroendocrine Tumor TherapyNew therapeutic targetsBiology of NETsNeuroendocrine tumor cell linesSingle-drug effectsHuman NET cell linesLocalized diseaseNET patientsSurvival benefitSystemic therapyRare tumorDrug effectsImmunohistochemical techniquesTherapeutic targetAnimal modelsNET biologyTumor cell linesHuman malignanciesHuman Neuroendocrine Tumor Cell Lines as a Three-Dimensional Model for the Study of Human Neuroendocrine Tumor Therapy
Wong C, Vosburgh E, Levine A, Cong L, Xu E. Human Neuroendocrine Tumor Cell Lines as a Three-Dimensional Model for the Study of Human Neuroendocrine Tumor Therapy. Journal Of Visualized Experiments 2012 DOI: 10.3791/4218-v.Peer-Reviewed Original Research
Academic Achievements & Community Involvement
activity American Association of Cancer Research
Professional OrganizationsMemberDetails2004 - Presentactivity American Society of Clinical Oncology
Professional OrganizationsMemberDetails2004 - Presentactivity American Society of Hematology
Professional OrganizationsMemberDetails2004 - Present
Get In Touch
Contacts
Email
Academic Office Number
Secondary Academic Office Number
Appointment Number
Clinical Inquiry Number
Office Fax Number
Mobile Phone Number
Mailing Address
Yale School of Medicine
West Haven VA Hospital, 950 Campbell Avenue
West Haven, CT 06516
United States